“In Iran, Cinna Gene Company is participating in the process of producing this vaccine, and the second phase of the clinical trial of the vaccine started and ended in the last two months and received the approval of the Ethics Committee of the Health Ministry,” Payam Tabarsi, one of the main Iranian researchers participating in the project, said on Saturday.
He added that the third phase of the clinical trial of the vaccine will start on Saturday, and noted, “17,000 people will participate in this phase and the third phase of the clinical trial will end within the next one or two months.”
Tabarsi said that the second phase of the clinical trial of the vaccine showed that SpikoGen creates 70% immunity in the body of receivers.
The first phase of the clinical trial was performed on volunteer Australians.
SpikoGen is a recombinant protein subunit vaccine.
Tabarsi had said in July that the SpikoGen vaccine works on a double-dose immunity platform, adding, “The production capacity of this vaccine stands at 5 million doses per month, and fortunately the infrastructures have been prepared and mass production will start necessary licenses are issued.”
Iran is producing different types of coronavirus vaccines indigenously and in cooperation with other states.
Head of the COV-Iran Barekat vaccine project at the Headquarters for the Execution of Imam Khomeini's Order Hassan Jalili announced early August that HEIKO has supplied the health ministry with 1.5mln doses of the indigenized coronavirus vaccine.
“Today, we delivered 200,000 new doses of coronavirus vaccine to the health ministry for public injection,” Jalili said last Sunday.
"In the past weeks, 1.3 million doses of COV-Iran Barekat vaccine were delivered to the health ministry, and thus the number of delivered vaccines increased to 1.5mln doses," he added.
Iran Shrewdly Negotiated JCPOA, Developed Civilian Nuclear Industry
